LEO Pharma appoints Christophe Bourdon as new CEO
31.1.2022 17:17:52 CET | LEO Pharma | Press release
LEO Pharma is taking significant steps to transform the company to become a competitive, global player in the growing dermatology market, successfully launch a global product portfolio and prepare the company for a public listing (IPO).
To lead this, the Board of Directors of LEO Pharma today announced the appointment of Christophe Bourdon as new CEO as of April 1, 2022.
“I am thrilled that Christophe Bourdon joins LEO Pharma as new CEO. Christophe Bourdon is an international and accomplished leader. I am confident that he is the right person to lead LEO Pharma’s transformation towards becoming a publicly listed leader in medical dermatology. The Board of Directors is looking forward to working closely with Christophe Bourdon and the Global Leadership Team on the next chapters of LEO Pharma’s growth journey,” said Chairman of the Board of Directors, Jesper Brandgaard.
Christophe Bourdon will join from a role as CEO of Orphazyme A/S. His previous roles include Senior Vice President, General Manager, U.S. Oncology Business, at US biotech Amgen Inc. where he also led commercialization planning of top-selling drugs on the global market. Prior to Amgen, Christophe Bourdon was Senior Vice President of Europe, Middle East, Africa, and Canada at Alexion as the company launched two breakthrough ultra-orphan drugs and negotiated payor access across UK, Germany, France, Italy, and Canada. Christophe Bourdon holds an MBA from IMD Business School (Switzerland) and a BA from ISG (France).
“I am excited to join LEO Pharma and bring my competences and experience into play as LEO Pharma goes through the next phases of its transformation. The company’s strong heritage appeals to me as well as the unique profile in medical dermatology. LEO Pharma has a huge potential for growth and for making a difference for people who need more treatment options for their skin conditions,” said Christophe Bourdon.
Contacts
Media Contact
Karen Frost,
kasfr@leo-pharma.com
Tel: +45 3166 1567
About LEO Pharma
About LEO Pharma
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 93 million patients in 130 countries. In 2020, the company generated net sales of DKK 10.133 billion.
For more information about LEO Pharma, visit www.leo-pharma.com.
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma to showcase new data highlighting the burden and unmet needs in Chronic Hand Eczema at ESCD 2026 in Copenhagen25.6.2026 13:00:00 CEST | Pressemeddelelse
New data show that chronic hand eczema can disrupt working lives and school days, with many patients reporting sick leave from work and worsening of symptoms during everyday activities.1 Findings from the DELTA FORCE and DELTA TEEN phase 3 studies highlight the heavy burden of chronic hand eczema across the life course – from impaired work productivity in adults to an impact on school life in adolescents.1,2
LEO Pharma’s net-zero and emissions reduction targets validated by SBTi8.6.2026 09:00:00 CEST | Pressemeddelelse
LEO Pharma has achieved Science Based Targets initiative (SBTi) validation for its net-zero climate targets, including its ambition to reach net-zero greenhouse gas emissions by 2050, alongside near-term goals to reduce Scope 1 and 2 emissions by 63% and Scope 3 emissions by 37.5% by 2035 With its targets now validated, LEO Pharma is shifting from target-setting to implementation, advancing 15 prioritized initiatives in its Climate Transition Plan while emphasizing the connection between environmental health and patient care
LEO Pharma lancerer LOQTORZI® (toripalimab) på hjemmemarkedet i Danmark7.5.2026 09:00:00 CEST | Pressemeddelelse
LOQTORZI® (toripalimab) lanceres i kombination med standardkemoterapi i Danmark som en ny førstelinjebehandling til voksne patienter med recidiverende eller metastatisk nasopharyngeal cancer, som ikke kan behandles med kirurgi eller strålebehandling (R/M NPC).¹ LOQTORZI® har vist en dokumenteret overlevelsesgevinst og kan udgøre en potentiel ny standardbehandling for patienter med fremskreden R/M NPC.² Langtidsdata fra det kliniske JUPITER-02-studie viser, at LOQTORZI® i kombination med kemoterapi giver vedvarende og signifikante forbedringer i både samlet overlevelse (OS) og progressionsfri overlevelse (PFS) sammenlignet med kemoterapi alene¹, hvilket etablerer en ny behandlingsmulighed for patienter med R/M NPC Lanceringen styrker LEO Pharmas Critical Care-portefølje på hjemmemarkedet i Danmark og demonstrerer virksomhedens engagement i at bringe nye behandlinger til patienter – via en etableret specialiseret kommerciel platform til hospitaler.
LEO Pharma delivers 9% revenue growth at CER in Q1 2026 and strengthens innovation pipeline5.5.2026 09:00:00 CEST | Pressemeddelelse
Ballerup, Denmark, 5 May, 2026 – In Q1 2026, LEO Pharma delivered robust revenue growth, driven by the dermatology portfolio, and improved profitability while significantly increasing commercial investments to support the global roll-out of Anzupgo® and the addition of Spevigo® to the portfolio. LEO Pharma also made significant strategic progress and advanced innovation through the acquisition of Replay’s next-generation gene therapy platform targeting rare genetic skin diseases, the approval of Enstilar® in China and the continued late-stage development activities for Anzupgo®, including FDA acceptance for review in adolescents with chronic hand eczema. Financial highlights LEO Pharma’s revenue increased by 4% to DKK 3,521 million, and by 9% at constant exchange rates (CER). The revenue growth was led by North America (30% at CER) and Rest of World (13% at CER), whereas sales in Europe declined by 1% at CER. Revenue from the dermatology portfolio grew by 11% (CER), driven by the strat
LEO Pharma bolsters rare skin disease focus through acquisition of Replay gene therapy platform30.4.2026 15:00:00 CEST | Pressemeddelelse
Acquisition adds high-payload herpes simplex virus (HSV) gene therapy targeting genetic skin diseases to LEO Pharma’s pipeline and further expands the company’s presence in rare dermatology Combines LEO Pharma’s six decades of dermatology expertise with Replay’s next-generation gene therapy platform to advance innovation for patients with rare skin diseases The lead program targets dystrophic epidermolysis bullosa (DEB), a devastating genetic skin disease with significant unmet medical need.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom